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Abstract: Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the 
central nervous system and represents one of the most common causes of chronic neurologic 
disability in young adults. All the current disease-modifying drugs are administered parenterally, 
and can be associated with varying degrees of injection site or infusion-related reactions. 
Together with other side effects, the parenteral route of administration is one of the key factors 
affecting adherence to therapy in multiple sclerosis. Fingolimod (FTY720) is an immunomodu-
lator that acts on sphingosine 1-phosphate (S1P) receptors and is the first oral drug approved 
by the US Food and Drug Administration for the treatment of relapsing-remitting multiple 
sclerosis. Downmodulation of S1P receptor type 1 (S1P1) slows the egress of lymphocytes from 
lymph nodes and recirculation to the central nervous system, reduces astrogliosis, and inhibits 
angiogenesis during chronic neuroinflammation. Fingolimod also regulates the migration of 
B cells and dendritic cells, and enhances endothelial barrier function. Results from Phase II 
and III clinical trials provide robust evidence of the efficacy of fingolimod in relapsing-remitting 
multiple sclerosis. While some caution should be exercised in terms of safety issues, the intro-
duction of fingolimod represents a great advance in the treatment of relapsing-remitting multiple 
sclerosis. The pharmacologic data on fingolimod and its efficacy and safety in multiple sclerosis 
are reviewed in this paper.
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Core Evidence clinical impact summary for [fingolimod/relapsing multiple sclerosis]
Outcome measure Evidence Implications
Disease-oriented evidence Clear efficacy in relapsing- 
remitting multiple sclerosis   
as measured on both  
clinical and MRi 
parameters. 
it may promote the 
prevention 
of disability accumulation  
and disease progression  
overtime (long-term  
follow-up studies  
are needed).
Clinical 54% reduction compared  
to placebo*
Annualized  
Relapse-rate
52% reduction compared  
to iFNB-1a i.m.§
EDSS progression HR for disease progression  
confirmed after 6 months = 0.63*
MRi
Brain volume Approximately 30% reduction in the 
rate of brain atrophy*§
No. of gadolinium-enhancing  
lesions
Significant reduction compared to 
placebo and iFNB 1a i.m.*§
No. of new or enlarged  
lesions on T2-weighted images
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Introduction
Multiple sclerosis is an autoimmune inflammatory demyeli-
nating disease of the central nervous system, and is one of 
the most common causes of chronic neurologic disability in 
young adults.1 It typically affects people during the most 
productive period of their lives, with a peak onset at age 
20–40 years. In the majority of cases (80%–90%), the disease 
at onset is characterized by a relapsing-remitting course, in 
which episodes of acute relapse, followed by full or partial 
recovery, are separated by periods of remission. In most 
patients, the relapsing-remitting phase is followed by a sec-
ondary progressive course, in which disability progressively 
accumulates despite the absence of acute exacerbations. In 
a smaller proportion of cases (10%–20%), the disease starts 
with a primary progressive course, and disability progres-
sively increases from the onset onwards.1 The pathogenesis 
of multiple sclerosis is still far from a full definition. How-
ever, evidence points to a multifactorial etiology, in which 
genetic and environmental factors contribute to the genesis 
of the disease. In terms of mechanisms, a large body of data 
indicates that myelin destruction, loss of oligodendrocytes, 
and varying degrees of axonal injury are sustained by the 
involvement of immunologic factors. In particular, both cel-
lular and humoral immune mechanisms play a central role 
in the genesis of the disease.1–3
To date, there is no cure for multiple sclerosis. However, 
over the last two decades, several therapies have been 
  developed, leading to a significant improvement in the clini-
cal outcome of the disease.1 These include the three different 
formulations of interferon-β (IFN-β), and glatiramer acetate, 
mitoxantrone, and natalizumab. According to currently 
accepted treatment protocols, IFN-β and glatiramer acetate 
are considered to be first-line treatments for relapsing- 
remitting multiple sclerosis, while mitoxantrone and natali-
zumab are considered second-line therapies which are generally 
reserved for patients who do not respond to the first-line 
agents or who cannot tolerate their side effects (Table 1).4
These therapies are mainly indicated for treatment of 
relapsing-remitting multiple sclerosis, for which clinical trials 
have shown a clear efficacy. Evidence of efficacy of immu-
nomodulatory and immunosuppressive therapies in the 
progressive phases of the disease are more limited, and only 
mitoxantrone and IFN-β 1b (the latter in Europe only) have 
been approved for secondary progressive multiple sclerosis.
IFN-β1b is the first immunomodulatory drug available 
for multiple sclerosis, and was approved by the US Food and 
Drug Administration (FDA) in 1993.5 Other formulations of 
IFN-β were approved in the following years, between 1996 
and 2002.6,7 The other immunomodulatory drug, glatiramer 
acetate, was approved in 1996.8 Both IFN-β and glati-
ramer acetate have documented clinical efficacy in relapsing-
  remitting multiple sclerosis. They reduce the relapse rate by 
about 30% and the accumulation of lesion load on brain mag-
netic resonance imaging (MRI) by about 70%.5–9 Their 
Table 1 Escalating therapy of multiple sclerosis
First-line therapies interferon-beta
Glatiramer acetate
(Azathioprine)
Second-line therapies Mitoxantrone
Natalizumab
Cyclophosphamide
Third-line therapy Hematopoietic autologous
Stem cell transplantation
(Continued)
Outcome measure Evidence Implications
Patient-oriented evidence
Discontinuation rate 10.2% at 12 months§ High rate of adherence,  
mainly due to the oral 
administration and  
the good tolerability. it 
may promote the efficacy 
of the drug in the long-
term.
16.8% at 24 months*
Quality of life measures Not available
Economic evidence
Not available
Notes: *FREEDOMS Study, §TRANSFORMS Study.
Abbreviations: iFNB, interferon beta; EDSS, Expanded disability status scale; MRi, magnetic resonance imaging.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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efficacy has been largely comparable in head-to-head trials.10,11 
Second-line therapies have higher efficacy than immuno-
modulatory drugs. Mitoxantrone, a chemotherapeutic agent, 
was approved in 2000 for relapsing-remitting multiple scle-
rosis and early secondary progressive multiple sclerosis. 
It reduces the relapse rate by approximately 42% and 
  accumulation of MRI lesion load by approximately 83%.12 
However, its use is limited due to cumulative cardiotoxicity 
and an increased incidence of acute leukemia.12
Natalizumab was initially approved in 2004. It reduces 
the relapse rate by 68% and occurrence of new lesions on 
brain MRI of 83%.9 However, it was voluntarily withdrawn 
from the market by the manufacturer after three cases of 
progressive multifocal leukoencephalopathy were reported.9 
After further review by the FDA, natalizumab returned to 
the market in 2006 but under a special prescribing program 
intended to monitor strictly the safety of the drug and the 
occurrence of new cases of progressive multifocal leukoen-
cephalopathy over time. The prescribing program was initi-
ated and promoted by the manufacturer. Similarly, other 
prescribing and monitoring programs have been developed. 
For instance, in Italy, the national drug agency (Agenzia 
Italiana per il Farmaco) has created a registry to assess the 
safety of natalizumab in all treated cases.13–15
All the current disease-modifying drugs are administered 
parenterally, and can be associated with varying degrees of 
injection site or infusion-related reactions. Together with 
other side effects, the parenteral route of administration is 
one of the key factors affecting adherence to therapy for 
multiple sclerosis.16 Therefore, there is a need for the devel-
opment of oral agents. The new generation of multiple 
sclerosis therapeutics includes fingolimod (Novartis Phar-
maceuticals) and cladribine (Merck Serono), that are in a 
more advanced stage of development. Other oral agents, 
currently in Phase III trials, are BG00012, a fumarate ester 
(Biogen), laquinimod (Teva Pharmaceuticals), and 
  teriflunomide (Sanofi-aventis).17
Cladribine is now under review by the FDA. Cladribine 
is an antineoplastic agent that is currently used to treat hairy 
cell leukemia. An oral formulation of cladribine has been 
tested in a single Phase III trial and was found to meet its 
primary endpoint. Indeed, there was a 58% relative reduction 
in annualized relapse rates compared with placebo.18 
  Fingolimod, a nonselective sphingosine 1-phosphate (S1P) 
receptor modulator,19 has been recently reviewed and 
approved by the FDA.20 Therefore, it is expected to be the 
first oral immunodulatory agent for multiple sclerosis to be 
launched. In the following sections we review pharmacologic 
aspects of fingolimod and data on its efficacy and safety in 
multiple sclerosis.
Fingolimod
Fingolimod (FTY720) is the prototype S1P receptor 
  modulator, and is a derivative of a natural product, myriocin, 
isolated from the ascomycete Isaria sinclairii.21 S1P is a 
sphingomyelin-derived second messenger that mediates 
several cellular responses, including proliferation, migration, 
cytoskeletal organization, and cell survival.22 It acts in both 
an autocrine and paracrine fashion by binding to five G 
protein-coupled receptors (S1P1–S1P5). The different iso-
forms of S1P receptors are unevenly expressed in humans. 
S1P1, S1P2, and S1P3 are widely expressed; S1P4 is expressed 
in lymphoid and hematopoietic tissues, while S1P5 is mainly 
expressed in the central nervous system.23,24 S1P1 is the pre-
dominant receptor on lymphocytes and is crucial for the 
regulation of lymphocyte trafficking.25,26 In the central ner-
vous system, S1P5 and S1P1 are predominantly expressed by 
oligodendrocytes, a target of immune attack in multiple 
sclerosis.27–30 The efficacy of fingolimod in experimental 
autoimmune encephalomyelitis, and in clinical trials of 
multiple sclerosis is largely attributed to its activity on S1P1 
receptors on lymphocytes and endothelial cells.19,31–34 Other 
possible actions leading to the favorable clinical outcome, 
including a direct central nervous system effect of   fingolimod, 
are currently being investigated. The chemical name of 
fingolimod is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-
1,3-diol hydrochloride, and its chemical structure is shown 
in Figure 1. It is water soluble at low micromolar concentra-
tions, with a molecular weight of 343.94.
Mode of action
FTY720 is a structural analog of intracellular sphingosine, a 
metabolic product of sphingomyelin, which is a constituent 
of the cell membrane. Like its analog, FTY720 is rapidly 
phosphorylated in vivo, yielding to FTY720-phosphate 
(FTY720-P). In vitro, FTY720-P can bind to four out of 
the five S1P receptors, namely S1P1, S1P3, S1P4, and S1P5. 
HO
HO
NH2 • HCl
Figure 1 Chemical structure of FTY720 hydrochloride.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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The therapeutic effects of FTY720 have been attributed to the 
action of the drug on the S1P1 receptor. In particular, down-
modulation of S1P1 on lymphocytes slows the egress of 
lymphocytes from lymph nodes and recirculation to the central 
nervous system,25,35 downmodulation of S1P1 on neural cells 
may reduce astrogliosis,30,36–41 and downmodulation of S1P1 
on migrating endothelial cells inhibits   angiogenesis during 
chronic neuroinflammation.42 FTY720 also regulates the 
migration of B cells and dendritic cells, and enhances endothe-
lial barrier function.43–46 Taken together, modes of action of 
FTY720 render the drug unique when compared with other 
multiple sclerosis therapies, particularly in terms of its poten-
tial neuroprotective and neuroregenerative effect.
Pharmacokinetics
After oral administration in humans, FTY720 is extensively 
absorbed ($85%), with a high apparent absolute oral 
  bioavailability (93%). Absorption is not affected by food. 
Studies in renal transplant recipients showed a linear, dose-
dependent relationship for the maximum concentration and 
the area under the concentration-time curve at a dosing range 
of 0.125–5.0 mg/day.47 Steady-state is reached in 1–2 months 
during once-daily dosing, with an estimated 12-fold accu-
mulation of blood levels from first dose to steady state. 
FTY720 distributes in red blood cells, with a fraction in 
blood of 86%, whereas FTY720-P has a smaller uptake in 
blood of ,17%. Both FTY720 and FTY720-P are highly 
protein bound (.99.7%). Protein binding is not altered by 
renal or hepatic impairment. FTY720 is mainly transformed 
by reversible stereoselective phosphorylation to FTY720-P, 
the active moiety. Therefore, drug interactions will not be a 
major issue, although agents that inhibit CYP4F activity may 
increase blood levels of fingolimod as recently reported for 
ketoconazole.48 FTY720 and FTY720-P are in dynamic 
equilibrium at steady state. Blood clearance of FTY720 is 
low (6.3 ± 2.3 L/hour), with a long average apparent terminal 
half-life (6–9 days). FTY720-P clearance is in parallel with 
FTY720 in the terminal phase, with similar half-lives for 
both. After oral administration, about 81% is slowly excreted 
in the urine as inactive metabolites. About 2.5% of FTY720 
and FTY720-P are excreted intact in the feces.49
Pharmacodynamics
Three main pharmacodynamic effects of FTY720 have been 
identified, ie, reduction of lymphocyte count, decrease of 
heart rate, and increased resistance of the small airways.
Lymphopenia is due to trapping of lymphocytes inside the 
secondary lymphoid organs.26,50,51 Blood lymphocyte counts 
reach a dose- and concentration-dependent nadir about six hours 
after the first dose. The nadir is maintained during daily dosing. 
At a 5 mg daily dose, up to 85% reduction in peripheral lym-
phocyte counts can occur. After dosing cessation, the lympho-
cyte count begins to increase within 2–3 days, with recovery 
of a normal lymphocyte count within 1–2 weeks after the ter-
mination of treatment in the majority of subjects on FTY720 
0.5 mg and 1.25 mg.49,52 However, not all lymphocyte subsets 
are equally affected, and antibody responses are differentially 
impaired, depending on the localization and dissemination of 
the antigen. FTY720 inhibits the induction of high-affinity, 
class-switched IgG antibodies after local administration of T 
cell-dependent antigens, whereas the production of low-affinity 
IgM antibody is not impaired.53,54 Therefore, FTY720 may 
Table 2 Clinical and magnetic resonance imaging efficacy of FTY720 in the Phase II and III trials
Endpoints Phase II trial FREEDOMS TRANSFORMS
Placebo FTY720 
1.25 mg
FTY720 
5.0 mg
Placebo FTY720 
1.25 mg
FTY720 
0.5 mg
IFNβ-1a FTY720 
1.25 mg
FTY720 
0.5 mg
Clinical
Annualized relapse rate 0.77 0.35 0.36 0.40 0.16 0.18 0.33 0.2 0.16
Relapse-free patients (%) 66 86 86 45.6 74.7 70.4 69.3 79.8 82.6
Absence of disability 
progression on the EDSS (%)
80 90 85 75.9 83.4 82.3 92.1 93.3 94.1
MRI
gd+ lesions (n) 2.2 ± 4.3 1.3 ± 5.8 0.3 ± 0.7 1.1 ± 2.4 0.2 ± 1.1 0.2 ± 0.8 0.51 ± 1.86 0.14 ± 0.58 0.23 ± 0.97
Absence of gd+ lesions (%) 47 77 82 65.1 89.8 89.7 80.8 91.2 90.1
New T2 lesions (n) 6.4 ± 9.2 3.0 ± 8.6 1.9 ± 2.6 9.8 ± 13.2 2.5 ± 5.5 2.5 ± 7.2 2.6 ± 5.8 1.5 ± 2.7 1.7 ± 3.9
Change in brain volume  
from baseline
-0.31 -0.22 -0.40 -1.31 -0.89 -0.84 -0.45 -0.30 -0.31
Abbreviations: MRi, magnetic resonance imaging; iFNβ, interferon beta; Gd+, gadolinium enhancing; EDSS, Expanded Disability Status Scale; FREEDOMS, FTY720 Research 
Evaluating Effects of Daily Oral therapy in Multiple Sclerosis; TRANSFORMS, Trial Assessing injectable interferon versus FTY720 Oral in Relapsing-Remitting Multiple Sclerosis.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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inhibit responses to antigens which require lymphocyte traf-
ficking, but does not impair humoral immunity when the antigen 
is widely distributed to most lymphoid organs.
Similar to S1P, FTY720-P activates the cardiac G protein-
gated potassium channel, resulting in lowering of heart rate. 
In the presence of persistent FTY720 exposure, S1P receptors 
are expected to internalize, attenuating the cardiac effect 
over time. The effect of FTY720 on heart rate can be con-
sidered similar to that of vagal mediation, and can include 
mild to moderate heart rate slowing and atrioventricular block 
(first- and second-degree Type I Wenckebach).
The acute agonist effects of FTY720 on S1P receptors in 
bronchial smooth muscle leads to mild bronchoconstriction. 
With regard to cardiac effects, the internalization of receptors 
over time is hypothesized to result in the attenuation of the 
pulmonary actions.
Use in multiple sclerosis
Efficacy
The earliest data on the efficacy of FTY720 in multiple 
sclerosis comes from a double-blind, placebo-controlled 
Phase II clinical trial.55 A total of 281 patients were 
  randomized to receive two doses of FTY720 (1.25 or 5 mg) 
or   placebo. Endpoints were analyzed at two time points, 
ie, months 0–6 (core phase) and at months 7–12 (extension 
phase). Blinding was maintained in the extension phase of 
the trial, and the previous placebo group was randomized to 
the two dose strengths of fingolimod, whereas the previously 
assigned fingolimod groups continued their existing 
  treatment. The primary endpoint of the study was the total 
number of contrast-enhancing lesions per patient accumulat-
ing over the course of six months. Secondary MRI measures 
at six months included the percentage of patients free of 
contrast-enhancing lesions, the volume of gadolinium- 
enhancing lesions, the total number of new T2 lesions, change 
in T2 lesion volumes from baseline MRI, and total brain 
volume. Secondary clinical endpoints analyzed at six months 
included annualized relapse rate, the total number of relapses, 
relative reduction in relapse rate versus placebo, and the 
proportion of relapse-free patients. At six months, both doses 
of FTY720 showed a significant effect in reducing the total 
cumulative number of contrast-enhancing lesions (Table 2). 
Moreover, despite the relatively short duration of the trial, 
the majority of the secondary MRI endpoints were also met 
(Table 2). The beneficial effect of fingolimod was also 
maintained during the extension phase. Furthermore, patients 
who switched from placebo to the active drug experienced a 
robust reduction in the number of contrast-enhancing lesions 
(within-group comparison at month 6 versus month 12). 
There was no effect of FTY720 on the tertiary outcome 
measure of disability, as measured on the Expanded   Disability 
Status Scale (EDSS).
The efficacy of FTY720 appeared to be comparable at 
both the low and high doses, but the dosage of 5 mg was 
associated with a higher risk of side effects. Therefore, the 
higher dosage was abandoned, and Phase III trials of fingoli-
mod were planned for the 1.25 mg dose and testing a lower 
dose of 0.5 mg. The first Phase III study of FTY720 in mul-
tiple sclerosis was a randomized, double-blind, parallel-group 
study, ie, TRANSFORMS (Trial Assessing Injectable Inter-
feron versus FTY720 Oral in Relapsing-Remitting Multiple 
Sclerosis).34 This was a three-arm study assessing the effects 
of daily doses of fingolimod 0.5 and 1.25 mg, compared with 
intramuscular IFN-β1a once a week, over a 12-month period. 
A total of 1292 patients were randomized to the three arms 
in a 1:1:1 ratio. Approximately one-half of the patients in 
the three groups had received previous treatment with dis-
ease-modifying drugs for multiple sclerosis (55%–58%). The 
primary efficacy endpoint was the annualized relapse rate. 
The main secondary endpoints were the number of new or 
enlarged T2 lesions at 12 months and time to confirmed dis-
ability progression as measured on the EDSS and the Multiple 
Sclerosis Functional Composite (MSFC).
TRANSFORMS was a success, because all endpoints 
(both primary and secondary) were met (Table 2). The results 
were not affected by previous treatment with other immu-
nomodulators. In comparison with IFN-β1a, the 0.5 and 
1.25 mg doses of fingolimod reduced the annualized relapse 
rate by approximately 52% and 39%, respectively. Both doses 
of FTY720 delayed the time to the first relapse, decreased 
the proportion of patients with confirmed relapses, and 
decreased the number of new MRI lesions and volume of 
contrast-enhancing lesions (Table 2). Even though disability 
was not a primary objective of the trial and the study was 
not powered to evaluate disability progression, FTY720 
showed a significant effect on MSFC score when compared 
with IFN-β1a. Progression on the EDSS did not significantly 
differ between FTY720 and IFN-β1a therapy. One of the 
most compelling results of TRANSFORMS for the treatment 
of relapsing-remitting multiple sclerosis was the evidence of 
higher efficacy of the oral drug in comparison with that of 
the currently accepted immunomodulatory agent.
The second Phase III trial of fingolimod was FREEDOMS 
(FTY720 Research Evaluating Effects of Daily Oral therapy Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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in Multiple Sclerosis).33 This study assessed the effects of 
daily doses of FTY720 0.5 mg or 1.25 mg, compared with 
placebo over a 24-month follow-up period. A total of 
1272 patients were randomized with a 1:1:1 ratio. The propor-
tion of   reviously treated patients was slightly lower than that 
of TRANSFORMS (40%–43%). However, the primary and 
secondary endpoints were similar to those described in 
TRANSFORMS. This study confirmed the beneficial effect 
of fingolimod in relapsing-remitting multiple sclerosis. Com-
pared with placebo, the 0.5 mg and 1.25 mg doses of fingoli-
mod reduced the annualized relapse rate by 54% and 60%, 
respectively. Time to the first relapse was significantly delayed 
and the proportion of relapse-free patients was significantly 
higher in the FTY720 groups. It is worth noting that in FREE-
DOMS, both the low and high doses of FTY720 were proven 
to be effective for lowering the risk of disability progression. 
In particular, the hazard ratio of progression on the EDSS 
confirmed at three months was 0.70 for the low dosage and 
0.68 for the high dosage. The corresponding values for EDSS 
progression confirmed at six months were 0.63 and 0.60. The 
MSFC scores remained consistently stable in both 
FTY720 groups, whereas they worsened in the placebo group. 
With regard to MRI parameters, both doses of fingolimod 
caused a significant reduction in the number of contrast-en-
hancing lesions at 24 months, as well as in the number of new 
or enlarged T2 lesions and in T2 lesion   volume change from 
baseline. The efficacy of FTY720 was maintained, also merg-
ing the MRI parameters in a unique score including both the 
absence of contrast-enhancing lesions at 24 months and new 
T2 lesions from baseline (Table 2). Interestingly, both doses 
of FTY720 significantly reduced T1 lesion volumes and brain 
volume loss when compared with placebo. The latter two MRI 
parameters are believed to be surrogate markers of disease 
activity in terms of brain tissue damage, and their improve-
ment may be related to a neuroprotective action of the drug. 
Moreover, the lack of “pseudoatrophy” (brain volume loss 
observed in the first 6–12 months of treatment due to reduced 
inflammation and related water content) in FTY720 trials 
seems to confirm that the mode of action of fingolimod may 
involve other effects (neuroprotective, neuroregenerative) 
beyond its anti-  inflammatory actions.
On the whole, results from Phase II and III trials of 
FTY720 for the treatment of relapsing-remitting multiple 
sclerosis are very promising. Further insights are expected 
from the ongoing extension of the fingolimod Phase III trial, 
FREEDOMS II. Patients originally randomized to placebo 
or fingolimod 1.25 mg are switched to the lower 0.5 mg dose, 
and this dose appears to be safer. Finally, in view of the 
neuroprotective and neuroregenerative potential of FTY720, 
a Phase III trial INFORMS (A double-blind, randomized, 
multicenter, placebo-controlled parallel-group study compar-
ing the efficacy and safety of 1.25 mg FTY720 administered 
orally once daily versus placebo in patient with primary-
progressive multiple sclerosis) has been launched in patients 
with primary progressive multiple sclerosis.
Safety and tolerability
In general, FTY720 was shown to be well tolerated in all the 
Phase II and III studies.33,34,55 In the Phase II core study, dis-
continuation rates due to side effects were low across all 
groups. No deaths were reported. Minor side effects included 
nasopharyngitis, headache, diarrhea, and nausea. Nasophar-
yngitis, diarrhea, and nausea were significantly more frequent 
in the 5 mg dose group than in the placebo group. The differ-
ence was not significant for the 1.25 mg group. As expected, 
lymphopenia was common, but was mainly asymptomatic. 
Peripheral blood lymphocyte counts dropped to 20%–30% of 
the baseline value. Among serious adverse events, bradycar-
dia, chest pain, first-degree atrioventricular block, dyspnea, 
hypertension, and an increase in liver enzymes with jaundice 
were reported. A squamous cell carcinoma also occurred. 
These events were absent in the placebo group. In the exten-
sion period of the Phase II trials, two severe infections 
occurred in patients who switched from placebo to active 
treatment (facial herpes zoster on 5 mg and enterocolitis on 
1.25 mg). Moreover, in the 5 mg dose group, a posterior 
reversible encephalopathy syndrome was diagnosed in a 
patient with no prior history of hypertension or renal disease, 
which improved promptly after drug discontinuation.
With regard to cardiac effects, FTY720 caused a reduction 
in heart rate within the first six hours by a mean 13.8 beats/ 
minute in the 1.25 mg group and 16.6 beats/minutes in the 
5 mg group. However, as expected from its pharmacodynam-
ics, the reduction in heart rate improved back towards baseline 
with continued FTY720 treatment. Bradycardia was symp-
tomatic in one patient who switched from placebo to the 
1.25 mg dose and three patients who switched to the 5 mg 
dose. All episodes of symptomatic bradycardia occurred within 
24 hours, and resolved spontaneously. Moreover, transient 
second-degree Wenckebach atrioventricular block occurred in 
four patients receiving FTY720 1.25 mg and five patients 
receiving 5 mg. With regard to bradycardia, atrioventricular 
block occurred within 24 hours of the start of therapy. One 
patient receiving FTY720 5 mg experienced a single four-beat 
episode of nonsustained ventricular   tachycardia. Blood pres-
sure decreased to 5–6 mmHg below baseline within 4–5 hours Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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of fingolimod treatment. However, this was followed by a 
sustained increase in blood pressure of 4–6 mmHg above 
baseline values after two months of fingolimod, with no further 
increase over time. For pulmonary effects, forced expiratory 
volume in one second (FEV1) significantly reduced from 
baseline values in 8.8% of patients treated with the high-dose 
of FTY720 in comparison with 2.8% of patients in the low-
dose group and 1.9% of patients on placebo. After six months 
of treatment, predicted forced vital capacity (FVC) values 
decreased significantly by 0.8% and 3.2% in the 1.25 and 5 mg 
groups, respectively. However, in the extension phase, FEV1, 
FVC, and CO diffusion capacity was not different from values 
observed at six months. In general, serious adverse events were 
more frequent in the high-dose group (5 mg). Indeed, the dos-
age of 5 mg was abandoned and further investigations focused 
on the dosage of 1.25 mg and 0.5 mg.
In TRANSFORMS, the overall incidence of adverse events 
was low. However, two deaths occurred in the 1.25 mg group. 
Both deaths were secondary to infections. In one case, fatal 
infection was a disseminated varicella zoster infection. The 
patient had no prior exposure to chickenpox and the primary 
exposure to chickenpox occurred while on FTY720 0.5 mg 
and concurrent steroid treatment for multiple sclerosis relapse. 
The other patient died of herpes simplex encephalitis. Two 
additional patients died after the study was discontinued, both 
in the low-dose fingolimod group. One patient died from 
aspiration pneumonia 11 months after drug   discontinuation. 
The second patient died from metastatic breast cancer 
10 months after stopping fingolimod. In TRANSFORMS, four 
other serious infections were reported in patients treated with 
FTY720, ie, two herpes simplex virus infections and two cases 
of appendicitis. Two appendicitis cases and one herpes simplex 
virus infection were also reported in the IFN-β1a group.
Other mild herpes simplex virus infections were 
observed in 12 patients receiving IFN-β1a, nine receiving 
FTY720 0.5 mg, and 23 receiving FTY720 1.25 mg. As 
reported in the Phase II trial, fingolimod was associated 
with bradycardia, second-degree atrioventricular block, and 
elevated liver enzymes. Respiratory events were mild and 
with a greater frequency on the 1.25 mg dose. Furthermore, 
two patients on 0.5 mg and four patients on 1.25 mg had 
macular edema, diagnosed within four months from the 
start of FTY720   treatment. In most cases, macular edema 
resolved within three months after drug discontinuation. 
Cancers were diagnosed in 12 subjects receiving FTY720, 
comprising skin cancers in 10 patients (all successfully 
treated with excision) and breast cancers in four patients, 
three of which were detected within four months of the start 
of therapy and one diagnosed after 11 months. One basal 
cell carcinoma was also observed in the IFN-β1a group.
The incidence of adverse events was also low in 
  FREEDOMS. However, three deaths occurred, two in the 
placebo group and one in the FTY720 1.25 mg group. 
Deaths in the placebo group were due to pulmonary embo-
lism and a road traffic accident. The death in the fingolimod 
group was due to suicide. The risk of infection was similar 
in all groups. Infections include urinary tract infections, 
herpes simplex virus infections, and lower respiratory infec-
tions. Bradycardia was associated with FTY720, and 
required treatment in only two cases. First-degree atrioven-
tricular block was reported in 20 patients on FTY720 0.5 mg, 
37 patients on 1.25 mg, and in six patients receiving placebo; 
second-degree atrioventricular block occurred in one patient 
receiving 0.5 mg and four patients on 1.25 mg. All the effects 
were observed within the first 24 hours after FTY720 onset; 
with continued drug administration, no significant effect on 
heart rate or conduction was seen over the 24-month study. 
FTY720 was also associated with a mild increase in mean 
systolic blood pressure (1.9–3.6 mmHg). Macular edema 
occurred in seven patients, all receiving FTY720 1.25 mg. 
It was diagnosed within three months after drug initiation 
and resolved within six months after drug discontinuation. 
Finally, skin cancers occurred in 11 patients (three receiving 
fingolimod 1.25 mg, four receiving 0.5 mg, and four receiv-
ing placebo), all successfully treated by excision.
Conclusion
Over the last two decades, first-line therapy for multiple 
sclerosis has been dominated by the use of immunomodula-
tory drugs, all administered parenterally (intramuscularly 
or subcutaneously). Until now, one of the most important 
unmet needs in multiple sclerosis treatment has been effica-
cious oral therapy. In September 2010, the FDA approved 
FTY720 (GilenyaTM) as first-line therapy for relapsing-re-
mitting multiple sclerosis at a dosage of 0.5 mg.20 The deci-
sion was made on the basis of efficacy and safety data from 
the Phase III TRANSFORMS and FREEDOMS trials.33,34 
A baseline electroencephalogram and monitoring for bra-
dycardia in the first six hours after the first administration 
is recommended. Monitoring for infective, ophthalmologic, 
liver, and pulmonary complications is also required.
The introduction of FTY720 among the available treatment 
strategies for relapsing-remitting multiple sclerosis is promis-
ing and exciting. Clinical trials have clearly provided robust 
evidence of the efficacy of the drug in reducing the relapse 
rate and, to a lesser extent, the risk of disability progression. Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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Moreover, the oral route of administration should achieve 
higher levels of treatment adherence in comparison with 
currently used immunomodulatory therapies. However, some 
caution is necessary. First, although the efficacy of immuno-
modulatory therapy appeared to be lower than for FTY720 in 
TRANSFORMS and parenteral administration is associated 
with poorer compliance than for oral preparations, the safety 
profiles of IFN-β and glatiramer acetate are well established 
by lengthy postmarketing experience.   Fingolimod has been 
associated with a higher risk of potentially severe adverse 
events, including infections, cardiac events, and cancers, 
so strict monitoring of long-term safety is necessary. Some 
examples can be drawn from the experience with 
  natalizumab. Biogen initiated an international program of 
surveillance. Moreover, a similar registry may be developed 
at a national level, as occurred in Italy, where a registry of 
all cases treated with natalizumab is kept by the National 
Drugs Agency.13–15 Second, multiple sclerosis frequently 
affects women in their child-bearing years. Information on 
the effects of FTY720 in pregnancy is lacking. In animal 
studies, fingolimod demonstrated developmental toxicity, 
including teratogenicity and embryolethality in rats. There 
are no relevant data in humans, and a pregnancy registry 
has been developed. In the meantime, evidence is accumu-
lating on the safety of immunomodulatory drugs in preg-
nancy and fetal outcomes.56
However, despite these caveats, fingolimod represents 
a great advance in the treatment of relapsing-remitting 
  multiple sclerosis. Its efficacy is sustained by a strong anti-
inflammatory effect, together with potential neuroprotective and 
neuroregenerative properties and the drug was generally safe 
and well tolerated in clinical trials. Its broad spectrum of action 
renders fingolimod a possible candidate for further research in 
other forms of multiple sclerosis, namely primary progressive 
multiple sclerosis and secondary progressive multiple sclerosis, 
in which inflammatory activity is less pronounced, and benefit 
may be derived from its neuroprotective effects.
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